stock
NTRA · Natera, Inc.
What Natera, Inc. reports to the SEC, read from its filings.
Open in the appPrice
The live NTRA price and today's change.
Sign in to see thisChart
Thirty days of daily bars, with signal levels drawn on them.
Sign in to see thisSignals
The latest signal group Nakagai's scanner recorded on NTRA.
Sign in to see thisOptions positioning
Gamma exposure levels from the options market.
Sign in to see thisTechnicals
Trend, momentum and volatility gauges per timeframe.
Sign in to see thisWhat it is
- Industry
- Services-Medical Laboratories (SIC 8071)
- Filer (SEC EDGAR)
- EDGAR filing index
- Shares outstanding
- 144,144,170 as of 2026-07-31 (XBRL frame CY2026Q2I)
Key stats
Valuation
- P/E
- Locked
- P/S
- Locked
- P/B
- Locked
- Enterprise value
- Locked
- EV/EBIT
- Locked
- FCF yield
- Locked
Margins
- Gross
- —
- Operating
- -10.7%
- Net
- -7.1%
Returns
- ROE
- -10.6%
- ROA
- -7.2%
Health
- Current ratio
- 3.0x
- Debt/equity
- —
Deep value
- NCAV
- $822.95M
- NCAV per share
- $5.71
- Price/NCAV
- Locked
- NNWC
- $612.15M
- NNWC per share
- $4.25
- Price/NNWC
- Locked
Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.
Sign in to see thisDebt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | $752.75M | — | -$75.79M | -$66.97M | 10-Q filed 2026-08-07 |
| 2026-03-31 | $696.64M | — | -$93.52M | -$85.09M | 10-Q filed 2026-05-08 |
| 2025-12-31 | $665.50M | — | -$22.79M | $47.26M | DEF 14A filed 2026-04-23 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2025-09-30 | $592.18M | — | -$97.58M | -$87.54M | 10-Q filed 2025-11-07 |
| 2025-06-30 | $546.60M | — | -$110.37M | -$100.94M | 10-Q filed 2026-08-07 |
| 2025-03-31 | $501.83M | — | -$79.18M | -$66.94M | 10-Q filed 2026-05-08 |
| 2024-12-31 | $476.06M | — | -$64.74M | -$53.77M | DEF 14A filed 2026-04-23 Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. Assembled from more than one filing; the filing above is only the newest of them. |
| 2024-09-30 | $439.76M | — | -$39.34M | -$31.59M | 10-Q filed 2025-11-07 |
- Assets
- $2.66B
- Equity
- $1.82B
Balance as of 2026-06-30.
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| 2025-12-31 | $2.31B | -$309.91M | -$208.16M | $109.11M |
| 2024-12-31 | $1.70B | -$222.29M | -$190.43M | $69.24M |
| 2023-12-31 | $1.08B | -$446.25M | -$434.80M | -$286.15M |
| 2022-12-31 | $820.22M | -$541.04M | -$547.80M | -$479.20M |
| 2021-12-31 | $625.49M | -$468.17M | -$471.72M | -$376.27M |
| 2020-12-31 | $391.00M | -$216.28M | -$229.74M | -$202.12M |
| 2019-12-31 | $302.33M | -$116.29M | -$124.83M | -$68.41M |
| 2018-12-31 | $257.65M | -$114.63M | -$128.15M | -$74.46M |
| 2017-12-31 | $209.63M | -$135.34M | -$137.63M | -$107.69M |
| 2016-12-31 | $212.51M | -$101.05M | -$100.33M | -$97.19M |
Company filings
since Wed Dec 10
events
Results
ResultsAug 68-KExecutive or director change
Executive or director changeJul 68-KExecutive or director change
Executive or director changeJun 168-K/AExecutive or director change, Shareholder vote results
Executive or director changeShareholder vote resultsJun 168-KExecutive or director change
Executive or director changeJun 58-KResults
ResultsMay 78-K
5% owners ()
T. Rowe Price Associates, Inc.
Stake update
Vanguard Capital Management
Passive stake
The Vanguard Group
Stake update
T. Rowe Price Associates, Inc.
Stake update
JPMORGAN CHASE & CO.
Stake update
Insiders, politicians and funds
Insider trades, last 90 days
Chapman Steven Leonard
CEO AND PRESIDENT, Director
Sale$526,144Oct 2, 9:35 PM ET
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
Sale$1,242,645Oct 2, 9:35 PM ET
Sheena Jonathan
Director
Sale$7,008,972Sep 25, 9:35 PM ET
Sheena Jonathan
Director
Sale$3,216,145Sep 17, 9:35 PM ET
Rabinowitz Matthew
EXECUTIVE CHAIRMAN, Director
Sale$34,797,271Sep 16, 9:35 PM ET
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
- Duquesne Family Office
Period Tue 30 Jun 2026
16.6%Added - Maverick Capital
Period Tue 30 Jun 2026
3.3%Added - Coatue Management
Period Tue 30 Jun 2026
1.4%Trimmed - ARK Investment Management
Period Tue 30 Jun 2026
1.2%Added - Viking Global
Period Tue 30 Jun 2026
0.3%New
News
Stories that named NTRA, and the market events around them.
Sign in to see thisBoard
Recent signals
Signals open up here once a member has posted about NTRA.
Signals are informational.
Posts · 0
No posts yet.
nakagai
Signals on NTRA come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Members post on the NTRA board